Doxazosin Tablet
Product Images NDC 71610-043

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 71610-043). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 4mg (71610 0043 60)

Doxazosin 4 mg oral tablets label showing 90 tablets per container. The label includes dosage strength, quantity, storage instructions, and manufacturer details including Apotex Inc. (Toronto, Canada) and repackager Aphena Pharma Solutions - Tennessee, LLC. Contains barcode and federal controlled substance classification (Rx Only).*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Doxazosin-structure (Doxazosin Structure)

Chemical structure of doxazosin mesylate, showing its characteristic ring systems and functional groups as related to the active ingredient doxazosin.*

FDA Label Image

Figure-1-study1 (Figure 1 Study1)

Two line graphs titled 'Figure 1 – Study 1' showing clinical study results. The left graph depicts the mean change in total symptom score from baseline over a 14-week treatment period, comparing Doxazosin Mesylate (N=50) and placebo (N=47). The right graph shows the mean increase in maximum urinary flow rate (mL/sec) from baseline for the same groups across the same time frame. Statistical significance markers indicate differences between treatment and placebo groups.*

FDA Label Image

Table-1 (Table 1)

A data table summarizing effectiveness data from placebo-controlled trials of Doxazosin tablets. It presents symptom scores and maximum flow rate measurements across three studies with different dosages and durations. The table includes baseline and mean change values for placebo and Doxazosin groups, highlighting statistical significance. On the right, a bar graph illustrates maximum flow rate and symptom score changes for placebo, 4 mg, and 8 mg Doxazosin doses in Study 2.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.